Novartis Q3 Preview: Zolgensma Back In The Spotlight
First sales of SMA gene therapy to be revealed
Analysts will be keen to hear about the launches of key new drugs Zolgensma and Mayzent as they ponder how long sales of Cosentyx can keep climbing.
You may also be interested in...
Sandoz has announced that partner Pear Therapeutics will now market alone the reSET and reSET-O digital therapeutics launched by the pair in the US almost a year ago. The move follows Richard Saynor taking charge of Sandoz as part of the Novartis unit’s current transformation.
Shares in Eylea-maker Regeneron slid after FDA approved Novartis's competing VEGF inhibitor for treating AMD, but some observers said investors had overreacted.
As Novartis files Cosentyx for non-radiographic axial spondyloarthritis, it is becoming increasingly clear that psoriasis will not be the blockbuster's revenue growth driver going forward.